Potential of Pm11 antimicrobial peptide against bovine mastitis pathogens

OBJECTIVE To investigate an alternative treatment for bovine mastitis by using Pm11 antimicrobial peptide.SAMPLE 5 bovine mastitis pathogens that were previously isolated from cows affected by either clinical or subclinical mastitis. PROCEDURES The current study introduces Pm11 antimicrobial peptide as an alternative treatment for bovine mastitis. The antibacterial activity of Pm11 was tested against Escherichia coli strain SCM1249, Klebsiella spp strain SCM1282, Staphylococcus aureus strain CM967, Streptococcus agalactiae strain SCM1084, and Streptococcus uberis strain SCM1310 using minimum bactericidal concentrations (MBCs) and time-kill kinetics. The pathogens' morphological changes were demonstrated using a scanning electron microscope (SEM). The cytotoxicity of Pm11 was assessed using the minimum hemolytic concentration assay.RESULTS MBCs ranged from 2.5 to 10 mu M and IC50 ranged from 0.32 to 2.07 mu M. Time-kill kinetics at MBC demonstrated that Pm11 reduced viable cell counts of S agalactiae strain SCM1084 and S uberis strain SCM1310 from 105 to 0 CFU/mL within 1 h. E coli strain SCM1249 and S aureus strain CM967 were reduced from 105 to 0 CFU/mL within 4 h. The average Pm11-induced hemolytic activity was < 10% for all Pm11 concentrations tested except at the maximum concentration tested (160 mu M: 10.19 +/- 2.29%). Based on SEM, Pm11 induced morphological and cellular changes in S aureus and E coli.CLINICAL RELEVANCE Pm11 antimicrobial peptide demonstrated in vitro antibacterial activity against the common bovine mastitis patho-gens E coli, S aureus, S agalactiae, and S uberis, except Klebsiella spp, and should be further investigated in vivo.